HC Wainwright Reiterates Buy Rating on REGENXBIO Inc. (RGNX)
HC Wainwright maintains its buy rating on REGENXBIO with a $26 price target, a 148.09% upside from the current price.
Key Points
- HC Wainwright reiterated its buy rating on REGENXBIO Inc. (RGNX) with a $26 price target on June 24, 2026.
- HC Wainwright's $26 price target implies 148.09% upside from REGENXBIO Inc.'s ($RGNX) current $10.48 share price.
- Shares of RGNX traded near $9.95 on Wednesday, with a market cap of about $468.9 million.
- Institutional activity shows BlackRock increased its stake by 25,997 shares, while State Street added 444,749 shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 24, 2026, HC Wainwright reiterated its buy rating on REGENXBIO Inc. (NasdaqGS: RGNX), maintaining a price target of $26. Analyst Yi Chen supports the firm's bullish outlook on the biotechnology company.
HC Wainwright & Co. vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in REGENXBIO
Institutional investors have been active in REGENXBIO Inc. BlackRock, Inc. increased its holdings by 25,997 shares, ending with 5,782,808 shares valued at approximately $48.5 million. State Street Corp also boosted its position significantly, adding 444,749 shares for a total of 2,731,485 shares worth around $22.9 million. Meanwhile, JPMorgan Chase & Co reduced its stake by 69,702 shares, bringing its total to 3,483,800 shares valued at about $27.1 million. Vanguard Capital Management LLC initiated a new position with 2,007,146 shares valued at approximately $16.8 million.
REGENXBIO Inc. Stock Up 8.5%
Shares of REGENXBIO, trading under the ticker RGNX on the NasdaqGS, were near $9.95 on Wednesday. The company has a market cap of roughly $468.9 million. The stock's 52-week range spans from $5.46 to $16.19, with a 50-day moving average of $7.95 and a 200-day moving average of $10.34. REGENXBIO has a beta of 1.027, indicating its price is slightly more volatile than the market. The firm's liquidity ratios show a current ratio of 2.62 and a quick ratio of 2.45, though it carries a high debt-to-equity ratio of 1178.24.
$RGNX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
REGENXBIO reported revenue of $87.8 million, reflecting a decline of 92.8% in growth. The company's earnings per share (EPS) stand at a negative $5.60, with a return on equity (ROE) of -196.43%. The net margin is at zero, indicating no profit. The next earnings report is anticipated on August 6, 2026.
Insider Buying and Selling at REGENXBIO Inc.
Several insiders at REGENXBIO made significant stock purchases on May 29, 2026. Daniel Tasse, Kenneth Mills, and David Stump each acquired 46,600 shares. Additionally, Kenneth Mills, Allan Fox, and Alexandra Glucksmann bought 9,807 shares each. These transactions were not under a pre-arranged 10b5-1 plan.
Analysts Set New Price Targets
On June 24, 2026, HC Wainwright & Co. reiterated its buy rating on REGENXBIO with a price target of $26. Earlier, on June 22, 2026, Baird maintained a buy rating with a $32 target, and Leerink Partners also maintained a buy rating with an $18 target. The consensus among 11 analysts is a buy recommendation, with a mean price target of $23.82.
About REGENXBIO Inc.
REGENXBIO Inc. is a biotechnology company based in Rockville, Maryland. It develops gene therapies using its NAV Technology Platform, targeting conditions like wet age-related macular degeneration and Duchenne muscular dystrophy. The company collaborates with AbbVie and Nippon Shinyaku to develop several treatments and licenses its technology to other firms. Founded in 2008, REGENXBIO is led by CEO Curran M. Simpson and employs 371 people.
Bottom Line
HC Wainwright's reiterated buy rating on REGENXBIO highlights continued confidence in the company's potential, despite recent revenue declines. Investors and analysts are watching closely as the company develops its gene therapy pipeline. Institutional activities and insider transactions might indicate varied perspectives on the company's future. Remember, the information in this article is based on past filings and reports, which may not reflect the most current positions or opinions.
Get REGENXBIO Inc. alerts
New 13F filings, insider trades, and analyst moves on $RGNX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.